SCHEMBL19084663

SCHEMBL19084663

CC(C)(C)c1nn2c(=O)cc(-c3cccc(C(=O)O)c3)[nH]c2c1-c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 4/20 0.52
ARF6 P62330 3/20 0.40
RXRA P19793 2/20 0.39
RXRB P28702 2/20 0.39
KDM4A O75164 2/20 0.39
KDM5A P29375 2/20 0.39
KDM4C Q9H3R0 2/20 0.39
KDM5B Q9UGL1 2/20 0.39
PDE5A O76074 2/20 0.39
MAP4K4 O95819 1/20 0.38
IDO1 P14902 1/20 0.38
CSNK2A1 P68400 1/20 0.37
CD74 P04233 1/20 0.37
MIF P14174 1/20 0.37
MARS1 P56192 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE7A Q13946 1/20 0.37
PDE1C Q14123 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19084615 0.91 PSD (0.52) PSDARF6CSNK2A1PDE1APDE1B
SCHEMBL19084516 0.83 PSD (0.51) PSDARF6RXRA
SCHEMBL19084681 0.83 PSD (0.51) PSDARF6IDO1PDE4DPDE7A
SCHEMBL19084690 0.79 PSD (0.49) PSDARF6
SCHEMBL19099435 0.79 PSD (0.60) PSDARF6
SCHEMBL1278782 0.77 ARF6 (0.58) PSDARF6
SCHEMBL19084511 0.77 PSD (0.57) PSDARF6
SCHEMBL19084604 0.76 PSD (0.52) PSDARF6
SCHEMBL19084543 0.75 PSD (0.58) PSDARF6
SCHEMBL19084616 0.75 PSD (0.52) PSDARF6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885RXRA 4502/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885ARF6 1/4885RXRA 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.